Matthew Thompson, MD, Named Endologix’s President and CEO

November 10, 2021—Endologix LLC announced it has appointed Dr. Matthew Thompson as its new President and Chief Executive Officer and to the Board of Directors. Dr. Thompson has served as the company’s Chief Medical Officer since 2016, overseeing the business development, medical affairs, regulatory, clinical, and research and development departments.

In April, Dr. Thompson led Endologix’s acquisition and integration of PQ Bypass.

“I am excited about the opportunity to lead such a dynamic and innovative organization,” said Dr. Thompson in the company’s announcement. “I will be completely committed to our physician customers and to the safety and health of their patients as we continue to work collaboratively with the US Food & Drug Administration and other global regulatory agencies to ensure we maintain the highest standards possible.

“In the next year, we will continue to drive market share gains with our family of [abdominal aortic aneurysm] products and prepare our regulatory submissions for our innovative long-lesion [peripheral artery disease] products being developed after our acquisition of PQ Bypass earlier this year.”

Dr. Thompson is Staff Surgeon, Department of Vascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation Ohio, and Visiting Professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Endologix also noted that interim Chief Executive Officer, Richard Mott, would return to his role as Executive Chairman of the Board of Directors.